NEW YORK (GenomeWeb) – Leerink today initiated coverage of Danaher with an Outperform rating and a $93 price target on the firm's shares. 

"We believe the forthcoming company separation allows for a sharpened focus and expanded capital deployment opportunities," analyst Dan Leonard said in a report, adding that he also sees a margin expansion opportunity. All of those factors combined should drive Danaher's stock to outperform the S&P, he said. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.